# Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

> **NCT06071767** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 36 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **BIOLOGICAL:** ChAdOx1.tHIVconsv1
- **BIOLOGICAL:** ChAdOx1.HIVconsv62
- **BIOLOGICAL:** MVA.tHIVconsv3
- **BIOLOGICAL:** MVA.tHIVconsv4
- **DRUG:** Vesatolimod (VES)
- **DRUG:** GS-5423
- **DRUG:** GS-2872
- **BIOLOGICAL:** MVA.tHIVconsv4
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06071767
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2028-04-29
- **Final completion:** 2029-08-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06071767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06071767, "Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06071767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*